- Higher high-sensitivity C-reactive protein (hsCRP) concentrations were associated with a greater risk for lung cancer in current and former smokers, but not in never smokers.
- There was no association in adenocarcinoma.
Why this matters
- Prior studies suggesting an association between CRP and lung cancer risk were underpowered to provide data based on smoking status.
- Findings suggest hsCRP as a prediagnostic marker of lung cancer, rather than a causal risk factor.
- Nested case-control study.
- Prediagnostic serum or plasma samples from 5299 matched lung cancer case-control pairs in the Lung Cancer Cohort Consortium.
- Funding: NIH; others.
- Median time from blood draw to lung cancer diagnosis was 6.8 years.
- Overall, 47% were current smokers, 28% former smokers, and 25% never smokers.
- Higher hsCRP concentration was associated with overall lung cancer (OR, 1.05; 95% CI, 1.03-1.08).
- Association observed for current (OR for doubling, 1.09; 95% CI, 1.05-1.13) and former (OR, 1.09; 95% CI, 1.04-1.14) smokers, but not never-smokers (OR, 0.95; 95% CI, 0.91-1.00).
- Association was highest for current/former smokers diagnosed in the first 2 years of follow-up (OR, 1.21; 95% CI, 1.13-1.29).
- No association in adenocarcinoma (OR, 0.98; 95% CI, 0.91-1.05).
- Single hsCRP measurement.